Drug Database
NA

naproxen (naproxen, Verex / naproxen, Biovail)

✓ Approved

Bausch Health Companies Inc. · PTGS1 · Small Molecule

What is naproxen?

naproxen is a small molecule developed by Bausch Health Companies Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namesnaproxen, Verex, naproxen, Biovail
CompanyBausch Health Companies Inc.
Drug ClassSmall Molecule
Molecular TargetPTGS1, PTGS2
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

naproxen acts on 2 molecular targets:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

naproxen is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved

Related Research Articles

PubMedSe pu = Chinese journal of chromatography2026-09-18

[Determination of 33 non-steroidal anti-inflammatory drug residues in horse urine by QuEChERS-ultra performance liquid chromatography-tandem mass spectrometry].

Zhang Xiao-Nan XN, Ma Zhi-Chao ZC, Liu An A, Huang Yuan Y et al.

Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to treat horses' injuries and pain due to long-term training and competitions. In equestrian competitions, NSAIDs do not affect the upper limit of a horse's athletic ability, but they can enable the horse to perform close to its maximum capacity by reducing inflammation and pain. This not only affects the competition results, but also fails to ensure the health and welfare of the horses. Therefore, it has become crucial to effectively monitor and control NSAIDs residues during equestrian competition. In this study, a rapid screening and determination method for 33 NSAIDs in horse urine was established using QuEChERS pretreatment combined with ultra performance liquid chromatography-tandem mass spectrometry (QuEChERS-UPLC-MS/MS). The pretreatment process, chromatographic conditions, and mass spectrometric conditions were also optimized. In brief, the target analytes in 1 mL of horse urine samples were extracted with 5 mL of acetonitrile. During extraction, 100 mg of NaCl was added as a salting-out agent, and the mixture was shaken for 3 min. Subsequently, the extract was purified using a QuEChERS method with 300 mg of anhydrous MgSO4, 40 mg of octadecylsilane-bonded silica (C18), and 40 mg of primary secondary amine (PSA) as sorbents. After centrifugation, the supernatant was dried under nitrogen and reconstituted. The 33 NSAIDs were separated on an Agilent Poroshell 120 EC-C18 analytical chromatographic column (100 mm×3.0 mm,2.7 μm) with gradient elution using (A) 0.1% formic acid aqueous solution and (B) methanol solution as the mobile phases. The gradient elution program was as follows: 0-1 min, 30%B; 1-3 min, 30%B-60%B; 3-12 min, 60%B-85%B; 12-12.1 min, 85%B-95%B; 12.1-14 min, 95%B; 14-14.1 min, 95%B-30%B; 14.1-17 min, 30%B. Then, the target analytes were determined by UPLC-MS/MS in dynamic multiple reaction monitoring (dMRM) mode with positive/negative ion switching. Quantification was performed using the matrix-matched external standard method. The results showed that the method can rapidly and simultaneously determine the 33 NSAIDs in horse urine. The analytes had good linear relationships within their respective ranges, with correlation coefficients of >0.99. The limits of detection (LODs) and quantification (LOQs) were 0.1-1.0 μg/L and 0.9-5.4 μg/L, respectively. The recoveries of the 33 NSAIDs in horse urine were between 70.8% and 123.8% at three spiked levels of LOQ, 20 μg/L and 200 μg/L. The relative standard deviations of all targeted compounds ranged from 1.9% to 14.8%. The method was applied to 10 actual horse urine samples. The results revealed the presence of three NSAIDs, including ketorolac, lornoxicam and naproxen, with contents ranging from < LOQ to 6.87 μg/L. According to the Equine Prohibited Substances List published by the Federation Equestre Internationale (FEI), ketorolac and naproxen are controlled medications. They are prohibited for use during competition period, as they may mask symptoms and aggravate clinical conditions. However, they are permitted for use during non-competition times. Lornoxicam is a banned substance and is strictly prohibited for use in horses at any time. The proposed method is simple, efficient and accurate, and is suitable for the simultaneous determination of the 33 NSAIDs residues in horse urine samples.

PubMedPaediatric drugs2026-09-16

How Organ Manifestations Beyond the Bone May Guide Risk Stratification and Treatment Decisions in Chronic Nonbacterial Osteomyelitis.

Inguscio Giulia G, Schnabel Anja A, Roberts Eve E, Hedrich Christian M CM

Chronic nonbacterial osteomyelitis is an autoinflammatory bone disease characterized by pronounced dysregulation of proinflammatory and anti-inflammatory cytokine production and release. Through innate immune dysregulation, patients with chronic nonbacterial osteomyelitis develop bone inflammation, pathological bone remodeling, and associated pain. Notably, secondary activation of adaptive immune mechanisms may contribute to phenotypic variability and the onset of additional tissue and organ involvement (joints, skin, gut). Currently used treatments are empiric, targeting inflammation and/or osteoclasts. While deemed efficacious across clinical cohorts internationally, in the absence of randomized controlled trials, they lack regulatory approval. While chronic nonbacterial osteomyelitis limited to bones frequently responds to anti-inflammatory treatment with naproxen or, in more severe cases, tumor necrosis factor inhibitors and/or osteoclast inhibition with bisphosphonates, patients with additional symptoms may require additional/different treatments targeting effector T cells and associated cytokines (such as interleukin-17 blockers, Janus kinase inhibitors). Thus, changing molecular, cellular, and phenotypic patterns throughout the disease course offer an opportunity for personalized treatment and suggest a 'window of opportunity' preventing the onset of additional organ involvement. However, 'tools' to guide personalized treatment approaches are currently lacking, and treatment is guided by clinical features, following a trial-and-error approach. This article reviews the available literature, deciphering shared immune mechanisms between chronic nonbacterial osteomyelitis and associated diseases that may guide individualized care. It focuses on shared and disease-specific molecular and cellular patterns of chronic nonbacterial osteomyelitis and associated diseases, delivering arguments for disease stage and phenotype specific treatments, including cytokine blockers and synthetic small-molecule inhibitors.

PubMedMethods and applications in fluorescence2026-09-15

Quantitative Environmental Monitoring of Pharmaceuticals in Complex Matrices using Isoreticular Ln-BDC Frameworks through Non-Covalent Interactions.

Medina-Ambriz Alan Raúl AR, Loera-Serna Sandra S, Alarcón-Flores G G, Garduño-Wilches Ismael I

Lanthanide-based metal-organic frameworks (Ln-MOFs) offer a unique combination of adsorption capabilities and tunable luminescent properties, making them promising materials for environmental applications. This study details the synthesis of a family of isoreticular Ln-MOFs (Ln = Sm, Eu, Tb, Dy) using benzene-1,4-dicarboxylic acid (BDC) as a linker, yielding materials with nanometric crystallite sizes. We explore their efficiency in removing four emerging contaminants (ECs) and systematically evaluate the impact of adsorption on their luminescent properties. While exhibiting a maximum adsorption of 50.2% for naproxen on Dy 2 (BDC) 3 , highlighting the influence of EC functional groups, the materials demonstrate superior functionality as a luminescent sensor. Notably, ciprofloxacin adsorption induces a significant and specific luminescence enhancement (up to 202.24% for Eu-MOF), suggesting great potential for luminescence-based chemical sensing applications. The consistent fitting to the Freundlich model supports the occurrence of adsorption on energetically heterogeneous surfaces. These findings underscore the versatility of Ln-MOF for environmental monitoring through a mechanism that combines adsorption and modulated luminescence.

PubMedJournal of controlled release : official journal of the Controlled Release Society2026-09-15

Enzymatically triggered in situ gelation of a multifunctional peptide for localized controlled release and conformal fracture repair.

Tang Xiaofu X, Wen Cheng C, Shang Yuna Y, Yang Huijun H et al.

Irregular fracture edges and gaps present significant challenges to bone healing. As versatile scaffolds for bone regeneration, hydrogels can effectively guide and facilitate tissue repair. Compared to preformed hydrogels, in situ gelation via a responsive sol-gel transition at the defect site offers superior flexibility, adaptability, and conformity, minimizing void cavities and establishing a more favorable environment for healing complex fractures. Peptides, as biogenic building blocks, can self-assemble into hierarchically structured hydrogels under specific stimuli. Given that alkaline phosphatase (ALP) is a key enzyme in bone mineralization and is highly expressed at the fracture site, we developed a phosphorylated peptide (NfFpYO) that undergoes ALP-triggered dephosphorylation, enabling direct in situ gelation on irregular fracture surfaces. Our results show that the resulting nanofibrous three-dimensional scaffold, functionalized with Gly-Pro-Hyp (GPO) motifs, promotes the migration, proliferation, and osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) in vitro. Moreover, the resulting nanofibrous hydrogel, which presents peptide-bound naproxen and fluorinated motifs, was associated with a less inflammatory and more repair-supportive macrophage-associated marker profile, enhanced osteogenic marker expression, and improved radiographic and histological fracture repair in a murine model. This study adapts a promising ALP-instructed peptide self-assembly strategy to the fracture-repair microenvironment through a multifunctional precursor design, providing a local shape-conformal and bioactive hydrogel platform with potential for complex fracture repair.

PubMedJournal of chemical information and modeling2026-09-14

Unraveling the R-Enantiomer Preference in Mirror-Image Cyclodextrin: An Integrated Multiscale Computational Study.

Li Hongye H, Liu Xindi X, Chen Yuhao Y, Wang Chaojie C et al.

L-β-Cyclodextrin (L-CD), the mirror-image isomer of native β-cyclodextrin, provides a conceptually novel chiral microenvironment for pharmaceutical enantioseparation; however, its full separation potential and recognition mechanism remain largely unexplored, hindering its rational development. Herein, a multiscale computational framework integrating high-throughput molecular docking, molecular dynamics (MD) simulations, and density functional theory (DFT) calculations was developed to elucidate the chiral recognition mechanism of L-CD toward three clinically drugs, namely baclofen (Bacl), naproxen (Nap), and propranolol (Prop). Batch docking of 150 enantiomer pairs reveals that L-CD discriminates approximately 57% of the evaluated species, with a distinct preference for R-enantiomers in the 200-300 Da range. Subsequent MD simulations further demonstrated that R-enantiomer complexes possess enhanced structural stability, tighter cavity adaptation, and more persistent hydrogen bonds. Binding free energy calculations consistently yield stronger binding affinities of L-CD for R-enantiomers across all three drugs, exemplified by R-Bacl/CD (-72.05 kJ/mol) vs. S-Bacl/CD (-67.99 kJ/mol), R-Nap/CD (-67.46 kJ/mol) vs. S-Nap/CD (-66.03 kJ/mol), and R-Prop/CD (-79.51 kJ/mol) vs. S-Prop/CD (-73.59 kJ/mol). Energy decomposition analysis further reveals that reduced steric hindrance and favorable electrostatic interactions contribute to the enhanced stability of R-enantiomer complexes. This multiscale framework provides atomic-level insights into dynamic chiral recognition by L-CD and establishes a robust theoretical foundation for the rational design of next-generation L-CD-based chiral separation materials.

PubMedCase reports in oncological medicine2026-09-11

Paraneoplastic Fever in a Patient With Cervical Carcinoma: A Diagnostic Challenge and Management Approach.

Masilenge Ingrid I, Mallya Lucylight L, Jandwa Ravinder R, Mallango Samwel S et al.

Persistent fever in patients with cancer presents a significant diagnostic challenge, particularly in settings where infectious diseases are highly prevalent. Neoplastic fever is an important noninfectious cause of fever that may mimic infection and result in unnecessary investigations, antimicrobial therapy, and delays in cancer treatment. We report a case of a 45-year-old female patient with advanced cervical carcinoma who presented with persistent high-grade fever unresponsive to antibiotics. An extensive infectious workup was negative. Following exclusion of alternative causes, a naproxen challenge was performed, resulting in rapid resolution of fever within 24 h. Fever recurred upon withdrawal and resolved again after naproxen reintroduction, supporting the diagnosis of neoplastic fever. Neoplastic fever should be considered early in cancer patients with persistent unexplained fever, particularly in tuberculosis- and malaria-endemic settings. Following exclusion of infection, the naproxen challenge may provide a simple and affordable diagnostic step to distinguish neoplastic fever from infectious causes, reduce unnecessary antimicrobial use, shorten diagnostic delays, and facilitate timely cancer-directed therapy.

+7533 more articles available with a free account

Sign up free to view all articles →

Ask about naproxen